afety of treatments for inflammatory bowel disease : Clinical practice uidelines of the Italian Group for the Study of Inflammatory Bowel isease ( IG-IBD )

Inflammatory bowel diseases are chronic conditions of unknown etiology, showing a growing incidence and prevalence in several countries, including Italy. Although the etiology of Crohn’s disease and ulcerative colitis is unknown, due to the current knowledge regarding THEIR pathogenesis, effecvailable online xxx tive treatment strategies have been developed. Several guidelines are available regarding the efficacy and safety of available drug treatments for inflammatory bowel diseases. Nevertheless, national guideeywords: lines provide additional information adapted to local feasibility, costs and legal issues related to uidelines nflammatory bowel disease edical treatments afety the use of the same drugs. These observations prompted the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) to establish Italian guidelines on the safety of currently available treatments for Crohn’s disease and ulcerative colitis. These guidelines discuss the use of aminosalicylates, ∗ Corresponding author at: Department of Systems Medicine, GI Unit, University “Tor Vergata” of Rome, Via Montpellier 1, 00133 Rome, Italy. E-mail address: biancone@med.uniroma2.it (L. Biancone). 1 These authors contributed equally to this work. ttp://dx.doi.org/10.1016/j.dld.2017.01.141 590-8658/© 2017 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved. ARTICLE IN PRESS G Model YDLD-3344; No. of Pages 21 2 L. Biancone et al. / Digestive and Liver Disease xxx (2017) xxx–xxx systemic and low bioavailability corticosteroids, antibiotics (metronidazole, ciprofloxacin, rifaximin), thiopurines, methotrexate, cyclosporine A, TNF antagonists, vedolizumab, and combination therapies. These guidelines are based on current knowledge derived from evidence-based medicine coupled with clinical experience of a national working group. Gast